Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

A Transcriptional Co-Repressor Protein Links Obesity to Breast Cancer Risk

By BiotechDaily International staff writers
Posted on 28 Feb 2013
Weight gain and high-carbohydrate diets increase risk of developing breast cancer due to the activity of the transcriptional co-repressor protein CtBP (C-terminal binding protein).

The CtBP protein family has gained wide scientific interest due to findings that identified its critical role in animal development and oncogenesis. These multifunctional proteins predominantly function as transcriptional co-repressors in the nucleus by recruiting various histone-modifying enzymes such as histone deacetylases, histone methylases, and a histone demethylase. They also perform several diverse cytosolic functions such as Golgi maintenance and in central nervous system synapses.

Investigators at the [US] National Cancer Institute (Bethesda, MD, USA) used advanced genomic techniques to profile levels of CtBP in breast cancer cells. They reported in the February 5, 2013, online edition of the journal Nature Communications that elevated levels of CtBP in patient tumors predicted shorter survival time.

A high level of CtBP was found to drive epithelial-to-mesenchymal transition, stem cell pathways, and genome instability. Depletion of CtBP or caloric restriction reversed gene repression and increased DNA repair. Several members of the CtBP-targeted gene network were selectively downregulated in aggressive breast cancer subtypes. This group included the BRCA1 tumor suppressor gene. Both CtBP promoter targeting and gene repression could be reversed by small molecule inhibition.

“Our new work suggests that targeting CtBP may provide a way of treating breast cancer and possibly preventing breast cancer,” said senior author Dr. Kevin Gardner, head of the transcription regulation section at the [US] National Cancer Institute. “Modifying diet and maintaining a healthy diet, combined with developing pharmacological ways of lessening CtBP activity may one day lead to a way to break the link between cancer and obesity. Research should continue to focus on the link between obesity, CtBP, and breast cancer. This will require more population-based studies and multidisciplinary teams of scientist to investigate these links.”

Related Links:

National Cancer Institute



Channels

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.